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Meningitis is a serious complication that may occur after
any neurosurgical procedure. Management becomes
especially challenging when the organism responsible is
multi-drug resistant. Multi-resistant Acinetobacter has
become one of the more common nosocomial pathogens
in hospitals.1
Acinetobacter species are non-motile, oxidase-negative,
gram-negative coccobacilli found commonly in soil and
water, but they can be part of normal flora. They are
opportunistic pathogens that readily colonize patients who
have compromised host defenses. A variety of human
infections caused by Acinetobacter species have been
documented, including nosocomial pneumonia (most
often related to endotracheal tubes or tracheostomies),
endocarditis, meningitis, skin and wound infections,
peritonitis (in patients receiving peritoneal dialysis), and
urinary tract infections. Sporadic cases of conjunctivitis,
osteomyelitis, and synovitis have also been reported.2
Multi-drug resistant pathogens are becoming common in
ICU settings and are very difficult to treat with commonly
available antibiotics.1 In many situations involving post-
neurosurgical meningitis, intrathecal use of antibiotics is
necessary to clear the infection. There is very limited
published experience with intrathecal use of Polymxin B in
South Asia. In this report, we share our experience of
successful intrathecal use of polymyxin B for the
treatment of multi-resistant Acinetobacter meningitis. 
CASE REPORT
A 25-year-old gentleman sustained head injury after a
road traffic accident and presented to the emergency
room with post-traumatic recurrent seizures. On
examination, his Glasgow Coma Score (GCS) was 7/15
(localizing pain but no eye/verbal response). Endotracheal
intubation was performed due to poor neurological status. 
A CT scan showed bi-frontal contusions with compound
frontal sinus and base of skull fractures. Craniotomy for
frontal reconstruction and debridement was performed.
The patient was weaned off the ventilator in 3 days and
discharged on day 14 with no focal neurological deficit.
One day after discharge he presented to the emergency
room with fever, drowsiness and a generalized tonic-clonic
seizure. Examination showed GCS 11/15 (E4, M5, V2)
and a repeat CT scan showed a ring-enhancing lesion in
r ight basal gangl ia, at the location of previous
intracerebral hemorrhage. Radiologic appearance of the
lesion was suggestive of an abscess with development of
hydrocephalus and acute cerebral edema.
An urgent ventriculostomy drain was inserted and frank
pus was drained. Gram stain revealed gram-negative
diplococci and culture grew Acinetobacter lwoffi i,
sensitive only to polymyxin B and resistant to imipenem,
ceftaz id ime, cefepime, p iperaci l l in- tazobactam,
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ABSTRACT
Multi-resistant gram-negative nosocomial meningitis is a serious life-threatening infection presenting a therapeutic
dilemma. We report a neurosurgical patient who developed a post-operative brain abscess due to multi-resistant
Acinetobacter Iwoffii, sensitive only to polymyxin B. Successful management was accomplished by administration of
intravenous and intrathecal polymyxin B. Rapid CSF sterilization occurred with excellent clinical recovery and without any
serious side-effects related to polymyxin B. To our knowledge this is the first reported case of intrathecal use of polymyxin B
from Pakistan.
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ampicillin-sulbactam, quinolones, and amikacin. The
pat ient remained vent i lated and was started on
intravenous polymyxin 750,000 units twice daily along
with intrathecal polymyxin B 50,000 units (5 mg) once
daily. Total treatment duration was two weeks of
intrathecal and 4 weeks of intravenous polymyxin B.
Remarkable recovery was noted over the next two weeks
and the patient was extubated on day 28 with GCS
14/15 (E4, M5, V5). CSF culture became negative 48
hours after starting intrathecal polymyxin B. A ventriculo-
peritoneal shunt was inserted on day 41 and he was
discharged home on day 50 of admission. Outpatient
follow-up three months post-discharge confirmed he was
doing well.
DISCUSSION
Approximately 60 - 70% cases of meningitis caused by
gram-negative bacilli occur following neurosurgical
procedures.3 Multiple antibiotic resistance threatens
successfu l  t reatment of  Acinetobacter infect ion
worldwide. Overuse of ultra-broad spectrum antibiotics
such as imipenem has been associated with reports of
several outbreaks caused by carbapenem-resistant
strains, often leaving polymyxins and ampici l l in-
sulbactam as the only antibiotics with in-vitro activity
against these organisms, rendering therapy of these
cases as a serious challenge.4,5 Experience with
nosocomial meningit is and ventr icul i t is fol lowing
neurosurgical procedures indicates that the most
favorable outcome results from removal of infected
shunts, creation of an external ventriculostomy opening,
and daily administration of systemic and intraventricular
bactericidal antibiotics capable of crossing the blood-
brain barrier easily.3
The case presented here posed a challenging problem
since the organism showed resistance to all antibiotics
including ceftazidime, cefepime, imipenem, ampicillin-
sulbactam and aminoglycosides, and was sensitive to
polymyxin B alone. Multi-resistant pathogens are
becoming more common in ICU settings, especially in
patients who have been treated with multiple broad
spectrum antibiotic agents, had invasive devices
implanted or procedures performed in the hospital, and
had prolonged stay in an intensive care unit.1,6 Recent
experience with the use of intravenous polymxin B is
mainly limited to these settings.
Polymyxin B is one of the earliest agents employed in the
treatment of gram-negative baci l lary meningit is,
particularly that due to Pseudomonas aeruginosa.7,8,9 Only
two polymyxins, B and E (colistin), have been produced
commercially; polymyxin B has been in clinical use more
commonly. Polymyxin B demonstrates potent bactericidal
activity against most strains of P. aeruginosa, Escherichia
coli, Enterobacter species, and Klebsiella species,
damaging the plasma membrane in a manner similar to
that of cationic detergents. It penetrates poorly into CSF,
and the presence of meningeal inflammation does not
enhance absorption.10 Beneficial reduction in cerebral
edema and endotoxin production has been demonstrated
in experimental studies in rabbits when high-dose
intravenous polymyxin is administered concurrently with
another antibiotic.11 
Use of polymyxin alone has been successful in therapy for
more than forty three patients with meningitis and
ventriculitis caused by a number of gram-negative
bacteria.4 Although several authors advocate the separate
use of polymyxin B intramuscularly, intravenously, or
intrathecally, cure rate seem to be more frequent among
patients receiving combination systemic and local therapy
(intrathecal or intraventricular) or local polymyxin B as an
adjunct to other systemic therapy.7,12 Sterilization of CSF
occurs promptly (within 24-48 hours) when therapy is
given in conjunction with surgical repair and/or foreign-
body removal.13 
The majority of reported patients received prolonged
intrathecal or intraventricular therapy with polymyxin B (3-
38 days; 13-205 mg). Most patients received 10-14 days
of therapy with a total dose of 30-50 mg (3-5 mg daily).
Our patient received a 14-day course with a total of 70
mg (5 mg intrathecally daily of pure polymyxin B base,
which is equivalent to 50, 000 units of polymyxin B). 
V O L .  4 ( 1 )  J A N  -  M A R   2 0 0 9P A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S  24
Table1 Serial CSF Analysis
CSF Analysis Day 1 Day 7 Day 14 Day 24
Glucose(mg/dl) 23 55 70 55
Chloride(mEq/L) 120 115 118 110
Protein(mg/dl) 114 715 398 96.1
TLC(per cu mm) 2800 304 40 05
Polymorphs(%) 90 60 70 *
Lymphocytes(%) 10 40 30 *
RBC(per u mm) 120 1346 40 *
Pus cells Numerous Few Few Rare
Gram stain +++ Nil Nil Nil
Culture¶ positive negative negative Negative
*Cells insufficient for differential count
¶CSF cultures negative 48 hours after starting intrathecal polymyxin B
CSF levels range from 1.2-112 U / ml in children receiving
10,000-40,000 U of polymyxin intrathecally.10 Bactericidal
activity in CSF was assayed in one patient who received
intrathecal polymyxin B and was cured. The CSF trough was
bacteriostatic at a 1:8 dilution and bactericidal at a 1:4
dilution.14 In vitro synergy of polymyxin B with imipenem and
other antimicrobial agents against Acinetobacter, Klebsiella,
and Pseudomonas species have been documented.15
Polymyxin B is nephrotoxic and neurotoxic and has been
associated with renal insufficiency, giddiness, neuromuscular
blockade, and hyponatremia when used parenterally; and
with pain, numbness, paresthesia, confusion, coma and
convulsions when used intrathecally. The chemical
arachnoiditis seen with polymyxin is B is dose-
dependent.9,13,16,17 The parenteral dose ranges from 2.5-3
mg / kg per day in two divided doses. The intrathecal dosage
is 5 mg once daily for adults, 2 mg daily for children <2
years of age, and 3-4 mg daily for older children.
Neurotoxicity is seen when the dosage exceeds 5 mg or
50,000 U per day.10 
Our patient did not develop any nephrotoxicity due to
polymyxin. He had prolonged seizures, which started prior to
administration of polymyxin B and may have been related to
the development of brain abscess and late post-traumatic
meningitis. The seizures were probably not related to the use
of polymyxin B as they subsided while the patient continued
to receive intrathecal polymyxin B.  
CONCLUSION
This report and our experience suggest the benefit of
reinstating polymyxin B as a potential life-saving
antimicrobial therapy for multi-resistant, gram-negative
meningitis. Intrathecal polymyxin B appears to be safe and
should be combined with an effective systemic agent to
improve efficacy of therapy and minimize emergence of
resistance. 
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